The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
|Videos|June 25, 2013
Dr. Chang on the TRINOVA-1 Trial in Ovarian Cancer
Author(s)David D. Chang, MD, PhD
David D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ovarian cancer.
Advertisement
David D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ovarian cancer.
There are three TRINOVA studies, Chang says, which Amgen has been involved with for years. In the TRINOVA-1 trial, patients with ovarian cancer, primary peritoneal cancer, and fallopian tube cancer were randomized to receive trebananib (AMG 386) or placebo in combination with weekly paclitaxel chemotherapy.
Trebananib is a peptibody designed to block angiopoietins 1 and 2, and therefore blocking angiogenesis, Chang says.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
5